Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bemiparin sodium - Rovi

X
Drug Profile

Bemiparin sodium - Rovi

Alternative Names: Anti-Factor Xa - Rovi; Badyket; Cibor; Hepadren; Heporax; Hibor; Ivor; Ivorat; Ivormax; LMWH-Rovi; Nautiol; RO-11; Zibor

Latest Information Update: 26 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rovi
  • Developer Berlin Chemie; Elder Pharmaceuticals; Menarini; Rovi; sigma-tau SpA; UCB; University of Navarra
  • Class Antithrombotics; Glycosaminoglycans; Low molecular weight heparins
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Small cell lung cancer

Highest Development Phases

  • Marketed Thromboembolism
  • Phase II Small cell lung cancer
  • Discontinued COVID 2019 infections; Diabetic foot ulcer

Most Recent Events

  • 26 Sep 2022 Discontinued - Phase-II for COVID-2019 infections in Spain (SC)
  • 07 Jun 2022 Syntax for Science and Fundación de investigación terminates a phase II trial in COVID-2019 infections in Spain (SC) due to lack of funding (NCT04420299)
  • 04 Jun 2020 Phase-II clinical trials in COVID-2019 infections in Spain (SC) (NCT04420299)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top